RIFTOS MKI: Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R DTC)

RIFTOS MKI: Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R DTC)

AnnualMeeting2017

3 years
442 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Rutstein, Vice President of Oncology Development of Bayer discusses the RIFTOS trial, which focused on the use of sorafenib for thyroid cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #6084: Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
Up Next Autoplay